Novo Nordisk Taps DJ Khaled for Wegovy Push as BMO Lifts Target to $44
Published on 11/13/2026 at 07:21 | Editorial boerse-global.de
Novo Nordisk has enlisted DJ Khaled as an advertising partner for Wegovy, pairing a celebrity endorsement with a fresh push behind its obesity franchise. The announcement came yesterday, the same day chief executive Mike Doustdar told the DR podcast "Sorte tal" that Denmark will likely rank among at least 20 markets where the Wegovy tablet is to be rolled out by the end of 2027.
The marketing offensive lands against a mixed backdrop in Germany. According to reports on Wednesday citing Handelsblatt, the launch of the Wegovy pill in Europe's largest economy is proceeding slowly — a characterization at odds with Novo's earlier assessment that the German rollout had gotten off to an encouraging start.
Guidance Raised After Nine-Month Results
Novo Nordisk lifted its full-year expectations on 4 November alongside results for the first nine months of 2026. Adjusted revenue growth and adjusted operating profit growth are now each projected at minus 2 to plus 2 percent at constant exchange rates, a band that permits either contraction or expansion. The prior forecast for both metrics had stood at minus 6 to 0 percent.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
In the third quarter of 2026, adjusted revenue rose 4 percent at constant currencies. Doustdar credited the obesity portfolio, pointing to sustained US demand for the Wegovy pill and the first international launches. Adjusted operating profit for the quarter climbed 27 percent at constant exchange rates to DKK 31.7 billion.
BMO Capital weighed in on 5 November, raising its price target on the NYSE-listed Novo Nordisk ADR from $40.00 to $44.00 while keeping a "Market Perform" rating. Analyst Evan Seigerman highlighted Wegovy pill revenue growth that beat market expectations, though he questioned whether that momentum can be sustained through 2027 — which is why the higher target did not come with an upgrade. Other analysts moved in different directions: one cut its target to DKK 312 with a neutral rating unchanged on 5 November, while another lifted its target to DKK 240 while retaining a sell recommendation.
Liver Data and a Research Exit
Clinical news also surfaced. On Sunday the company reported a post-hoc ESSENCE analysis in adults with MASH and liver scarring, in which liver-related measures predominantly favored semaglutide over placebo. Novo Nordisk explicitly labeled the exploratory analysis as hypothesis-generating.
On the partnership front, Novo Nordisk is walking away from its research collaboration with Korro Bio. Per a Korro regulatory filing, the company notified its partner on 3 November of the termination of the research cooperation and license agreement, effective 1 February 2027. No second research milestone was designated and no milestone payments were earned, according to Korro's disclosure to the SEC.
Ad
Novo Nordisk Stock: New Analysis - 13 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
